Synthesis of methylene- and difluoromethylenephosphonate analogues of uridine-4-phosphate and 3-deazauridine-4-phosphate

Journal of Organic Chemistry

Volumn 71, Issue 25, 2006, Pages 9420-9430

  Taylor, Scott D ^a   Mirzaei, Farzad ^a   Sharifi, Ali ^a   Bearne, Stephen L ^b  

^a UNIVERSITY OF WATERLOO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CHEMICAL MODIFICATION; ENZYME INHIBITION; ENZYMES; ESTERS; OXYGEN; PHOSPHATES;

ACETATE DEPROTECTION; HIGH ENERGY INTERMEDIATES; NUCLEOSIDE; THERAPEUTIC AGENTS;

CATALYSIS;

ADENOSINE TRIPHOSPHATE; CARBENE; CYTIDINE TRIPHOSPHATE; CYTIDINE TRIPHOSPHATE SYNTHASE; FLUORINE DERIVATIVE; GLUTAMINE; NUCLEOSIDE; PHOSPHONOACETIC ACID; PYRIDINOL; SODIUM DERIVATIVE; URIDINE DERIVATIVE; URIDINE TRIPHOSPHATE;

ARTICLE; DECARBOXYLATION; DEPHOSPHORYLATION; DEPROTECTION REACTION; ENERGY; ENZYME MECHANISM; FLUORINATION; MOLECULAR STABILITY; REACTION ANALYSIS; SYNTHESIS;

CLODRONIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; URACIL NUCLEOTIDES;

EID: 33845514316     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo0617666     Document Type: Article

References (50)

1. (a) Jordheim, L. P.; Galmarini, C. M.; Dumontet, C. Recent Pat. Anti-Cancer Drug Discovery 2006, 1, 163.
2. (b) Carroll, S. S.; Olen, D. B. Infect. Disord.: Drug Targets 2006, 6, 17.
3. (a) Long, C. W.; Levitzki, A.; Koshland, D. E., Jr. J. Biol. Chem. 1979, 245, 80.
4. (b) Koshland, D. E., Jr.; Levitzki, A. Biochemistry 1971, 10, 3365.
5. (c) Long, C. W.; Pardee, A. B. J. Biol. Chem. 1967, 242, 4715.
6. (d) von der Saal, W.; Villafranca, J. J.; Anderson, P. M. J. Am. Chem. Soc. 1985, 107, 703.
7. (e) von der Saal, W.; Anderson, P. M.; Villafranca, J. J. J. Biol. Chem. 1985, 260, 14993.
8. (f) Levitzki, A.; Koshland, D. E., Jr. Biochemistry 1972, 11, 241.
9. (g) Levitzki, A.; Koshland, D. E., Jr. Biochemistry 1971, 10, 3365.
10. (h) Lewis, D. A.; Villafranca, J. J. Biochemistry 1989, 28, 8454.
11. McPartland, R. P.; Wang, M. C.; Bloch, A.; Weinfeld, H. Cancer Res. 1974, 34, 3107.
12. Kang, G. J.; Cooney, D. A.; Moyer, J. D.; Kelley, J. A.; Kim, H.-Y.; Matquez, V. E.; Johns, D. G. J. Biol. Chem. 1989, 264, 713.
13. (a) Barlogie, B.; Plunkett, W.; Raber, M.; Latreille, J.; Keating, J.; McCredie, K. B. Cancer Res. 1981, 41, 1227.
14. (b) Mills-Yamamoto, C.; Lauzon, G. J.; Peterson, A. R. P. Biochem. Pharmacol. 1978, 27, 181.
15. (c) Momparler, R. L.; Momparler, L. F. Cancer Chemother. Pharmacol. 1989, 25, 51.
16. (d) Momparler, R. L.; Bouffard, D. Y.; Momparler, L. F.; Marquet, J.; Zittoun, J.; Marie, J.-P.; Zittoun, R. Int. J. Cancer 1991, 49, 573.
17. (e) Momparler, R. L.; Vesely, J.; Momparler, L. F.; Rivard, G. E. Cancer Res. 1979, 39, 573.
18. (f) Bouffard, D. Y.; Momparler, L. F.; Momparler, R. L. Anti-Cancer Drugs 1994, 5, 223.
19. Savickiene, J.; Gineitis, A. Int. J. Biochem. Cell Biol. 2003, 35, 1482.
20. (a) Wolfenden, R. Acc. Chem. Res. 1972, 5, 10.
21. (b) Wolfenden, R. Annu. Rev. Biophys. Bioeng. 1976, 5, 271.
22. (a) Blackburn, G. M. Chem. Ind. (London) 1981, 134.
23. (b) Lazarus, R. A.; Benkovic, P. A.; Benkovic, S. J. Arch. Biochem. Biophys. 1979, 197, 218.
24. (c) Engel, R. Chem. Rev. 1977, 77, 349.
25. Honjo, M.; Maruyama, T.; Horikawa, M.; Balzarini, J.; de Clercq, E. Chem. Pharm. Bull. 1987, 35, 3227.
26. Maruyama, T.; Kimura, S.; Honjo, M. Org. Prep. Proced. Int. 1988, 20, 485.
27. (a) Kim, C.-H.; Marquez, V. E.; Mao, D. T.; Haines, D. R.; McCormack, J. J. J. Med. Chem. 1986, 29, 1374
28. (b) Schlieper, C. A.; Wemple, J. Nucleosides Nucleotides 1984, 3, 369.
29. (a) Vorbruggen, H.; Korlikiewicz, K. Angew. Chem., Int. Ed. Engl. 1976, 15, 689.
30. (b) Yamane, A.; Inoue, H.; Ueda, T. Chem. Pharm. Bull. 1980, 28, 157.
31. Acevedo, O. L.; Andrews, R. S.; Dunkel, M.; Cook, P. D. J. Heterocycl. Chem. 1994, 31, 989.
32. (a) Bischofberger, N. Tetrahedron Lett. 1987, 28, 2821.
33. (b) Blanalt-Feidt, S.; Doronina, S. O.; Behr, J.-P. Tetrahedron Lett. 1999, 40, 6229.
34. Bradley, J. C.; Buechi, G. J. Org. Chem. 1976, 41, 699.
35. Giese, B.; Linker, T. Synthesis 1992, 1-2, 46.
36. 1H NMR spectrum was not reported.
37. Freeman, S.; Irwin, W. J.; Schwalbe, C. H. J. Chem. Soc., Perkin Trans. 2 1991, 263.
38. Warren, S. G. J. Chem. Soc. C 1966, 1349.
39. Martell, A.; Langohr, M. F. J. Chem. Soc., Chem. Commun. 1977, 342.
40. (a) Differding, E.; Duthaler, R. O.; Kreiger, A.; Ruegg, G. M.; Schmit, C. Synlett 1991, 395.
41. (b) Taylor, S. D.; Kotoris, C., Dinaut, A. N.; Chen. M.-J. Tetrahedron 1998, 54, 1691.
42. Alberg, D. G.; Lauhon, C. T.; Nyfeler, R.; Fassler, A.; Bartlett, P. A. J. Am. Chem. Soc. 1992, 114, 3535.
43. Uchida, M.; Tabusa, F.; Komatsu, M.; Morita, S.; Kanbe, T.; Nakagawa, K. Yakugaku Zasshi 1985, 105, 1040.
44. Ochai, E. J. Org. Chem. 1953, 18, 534.
45. Boekelheide, V.; Lehn, W. L. J. Org. Chem. 1961, 26, 428.
46. Shiozawa, A.; Masahiro, S.; Kazuto, S.; Ichiro, K.; Narita, K.; Inubushi, A.; Araki, J. Japn. Patent 06080635, 1994.
47. This was discovered after compound 3 was prepared, and so phosphonate 31 was not used for the synthesis of compound 3. In any case, we preferred methyl-protecting groups as opposed to ethyl-protecting groups for phosphonate protection since methyl groups are removed more readily by TMSBr than ethyl groups; this reduces the compounds exposure to TMSBr which can cause side reactions and lower yields. We would have preferred methyl protection for the synthesis of compound 4; however, this was not practical.
48. Brossette, T.; Le Faou, A.; Goujon, L.; Valleix, A.; Creminon, C.; Grassi, J.; Mioskowski, C.; Lebeau, L. J. Org. Chem. 1999, 64, 5083.
49. Kurz, T.; Schluter, K.; Kaula, U.; Bergmann, B.; Walter, R. D.; Geffken, D. Bioorg. Med. Chem. 2006, 14, 5121.
50. Rollet, F.; Richard, C.; Pilichowski, J.-F.; Aboab, B. Org. Biomol. Chem. 2004, 2, 2253.